Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
Song Y, Cao J, Zhang Q, Li C, Qiu L, Qi J, Zhang H, Li W, Liu L, Jing H, Zhou K, Zhang W, Zhang L, Li D, Zou L, Yang H, Qian W, Zhou H, Hu J, Yin H, Fu S, Fan S, Xu Q, Wang J, Jia X, Dai G, Su W, Zhu J.
Song Y, et al. Among authors: xu q.
Haematologica. 2024 Jan 18. doi: 10.3324/haematol.2022.282401. Online ahead of print.
Haematologica. 2024.
PMID: 38235512
Free article.